Cognitive Indicators of Transition to Preclinical and Prodromal Stages of Alzheimer's Disease in Down Syndrome

Overview

Journal Alzheimers Dement (Amst)

Date 2020 Sep 30

PMID 32995465

Citations 24

Authors

Sigan L Hartley

Benjamin L Handen

Darlynne Devenny

Dana Tudorascu

Brianna Piro-Gambetti

Matthew D Zammit

Charles M Laymon

William E Klunk

Shahid Zaman

Annie Cohen

Bradley T Christian

Affiliations

Soon will be listed here.

Abstract

Introduction: There is a critical need to identify measures of cognitive functioning sensitive to early Alzheimer's disease (AD) pathophysiology in Down syndrome to advance clinical trial research in this at-risk population. The objective of the study was to longitudinally track performance on cognitive measures in relation to neocortical and striatal amyloid beta (Aβ) in non-demented Down syndrome.

Methods: The study included 118 non-demented adults with Down syndrome who participated in two to five points of data collection, spanning 1.5 to 8 years. Episodic memory, visual attention and executive functioning, and motor planning and coordination were assessed. Aβ was measured via [C-11] Pittsburgh Compound-B (PiB) PET.

Results: PiB was associated with level and rate of decline in cognitive performance in episodic memory, visual attention, executive functioning, and visuospatial ability in models controlling for chronological age.

Discussion: The Cued Recall Test emerged as a promising indicator of transition from preclinical to prodromal AD.

Citing Articles

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome.

Schworer E, Handen B, Petersen M, OBryant S, Peven J, Tudorascu D Alzheimers Dement (Amst). 2024; 16(2):e12582.

PMID: 38623384 PMC: 11016818. DOI: 10.1002/dad2.12582.

Prodromal Alzheimer's disease can affect activities of daily living for adults with Down syndrome.

Listwan T, Krinsky-McHale S, Kovacs C, Lee J, Pang D, Schupf N Alzheimers Dement (Amst). 2024; 16(1):e12562.

PMID: 38476636 PMC: 10927922. DOI: 10.1002/dad2.12562.

Neurofilament light chain concentration mediates the association between regional medial temporal lobe structure and memory in adults with Down syndrome.

DiProspero N, Sathishkumar M, Janecek J, Smith A, McMillan L, Petersen M Alzheimers Dement (Amst). 2024; 16(1):e12542.

PMID: 38348178 PMC: 10859879. DOI: 10.1002/dad2.12542.

Characterizing the emergence of amyloid and tau burden in Down syndrome.

Zammit M, Betthauser T, McVea A, Laymon C, Tudorascu D, Johnson S Alzheimers Dement. 2023; 20(1):388-398.

PMID: 37641577 PMC: 10843570. DOI: 10.1002/alz.13444.

AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.

Hartley S, Handen B, Tudorascu D, Lee L, Cohen A, Schworer E Alzheimers Dement. 2023; 20(1):366-375.

PMID: 37641428 PMC: 10840615. DOI: 10.1002/alz.13446.

References

Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65(11):1509-17. PMC: 2636844. DOI: 10.1001/archneur.65.11.1509. View

Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, Mayeux R . Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology. 1998; 50(4):991-5. DOI: 10.1212/wnl.50.4.991. View

Tudorascu D, Minhas D, Lao P, Betthauser T, Yu Z, Laymon C . The use of Centiloids for applying [C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimers Dement (Amst). 2018; 10:332-339. PMC: 6024172. DOI: 10.1016/j.dadm.2018.03.006. View

Temple V, Jozsvai E, Konstantareas M, Hewitt T . Alzheimer dementia in Down's syndrome: the relevance of cognitive ability. J Intellect Disabil Res. 2001; 45(Pt 1):47-55. DOI: 10.1046/j.1365-2788.2001.00299.x. View

Firth N, Startin C, Hithersay R, Hamburg S, Wijeratne P, Mok K . Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Ann Clin Transl Neurol. 2018; 5(6):741-751. PMC: 5989753. DOI: 10.1002/acn3.571. View

Farrer M, Crayton L, Davies G, Oliver C, Powell J, Holland A . Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome. Neuroreport. 1997; 8(7):1645-9. DOI: 10.1097/00001756-199705060-00018. View

Lott I, Head E . Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019; 15(3):135-147. PMC: 8061428. DOI: 10.1038/s41582-018-0132-6. View

Jack Jr C, Knopman D, Jagust W, Shaw L, Aisen P, Weiner M . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9(1):119-28. PMC: 2819840. DOI: 10.1016/S1474-4422(09)70299-6. View

Schupf N, Winsten S, Patel B, Pang D, Ferin M, Zigman W . Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome. Neurosci Lett. 2006; 406(3):298-302. DOI: 10.1016/j.neulet.2006.07.062. View

10.

Mann D, Esiri M . The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 1989; 89(2-3):169-79. DOI: 10.1016/0022-510x(89)90019-1. View

11.

Nelson L, Siddarth P, Kepe V, Scheibel K, Huang S, Barrio J . Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome. Arch Neurol. 2011; 68(6):768-74. PMC: 3261613. DOI: 10.1001/archneurol.2011.104. View

12.

Annus T, Wilson L, Hong Y, Acosta-Cabronero J, Fryer T, Cardenas-Blanco A . The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2015; 12(5):538-45. PMC: 4867786. DOI: 10.1016/j.jalz.2015.07.490. View

13.

Wisniewski K, Wisniewski H, Wen G . Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985; 17(3):278-82. DOI: 10.1002/ana.410170310. View

14.

Gagliardi G, Epelbaum S, Houot M, Bakardjian H, Boukadida L, Revillon M . Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). J Alzheimers Dis. 2019; 70(3):811-824. DOI: 10.3233/JAD-180966. View

15.

Devenny D, Krinsky-McHale S, Sersen G, Silverman W . Sequence of cognitive decline in dementia in adults with Down's syndrome. J Intellect Disabil Res. 2000; 44 ( Pt 6):654-65. DOI: 10.1046/j.1365-2788.2000.00305.x. View

16.

Adams D, Oliver C, Kalsy S, Peters S, Broquard M, Basra T . Behavioural characteristics associated with dementia assessment referrals in adults with Down syndrome. J Intellect Disabil Res. 2008; 52(Pt 4):358-68. DOI: 10.1111/j.1365-2788.2007.01036.x. View

17.

Cummings J, Fox N, Vellas B, Aisen P, Shan G . Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2018; 5(2):103-109. DOI: 10.14283/jpad.2018.13. View

18.

Holland A, Hon J, Huppert F, Stevens F . Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect Disabil Res. 2000; 44 ( Pt 2):138-46. DOI: 10.1046/j.1365-2788.2000.00263.x. View

19.

Rubenstein E, Hartley S, Bishop L . Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurol. 2019; 77(2):262-264. PMC: 6820036. DOI: 10.1001/jamaneurol.2019.3666. View

20.

Phillips B, Loveall S, Channell M, Conners F . Matching variables for research involving youth with Down syndrome: Leiter-R versus PPVT-4. Res Dev Disabil. 2013; 35(2):429-38. PMC: 3946670. DOI: 10.1016/j.ridd.2013.11.016. View